The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.
Open accessAbstract
Theophylline has been a mainstay in the treat- ment of asthma for over 50 years.Its thera- peutic value stems from a combination of anti- inflammatory and bronchodilator activities in addition to its ability to increase diaphragmatic contractility.14Although the pharmacological effects of theophylline have been studied extensively both in the laboratory and in the clinic, the molecular mechanisms res- ponsible for its activity in asthma remain ill defined.In fact, several cellular activities probably contribute to its action, including cyclic nucleotide phosphodiesterase inhibi- tion,' 5 adenosine receptor antagonism,6 stimulation of catecholamine release,7 and a poorly understood ability to increase the num- ber and activity of suppressor T lymphocytes.8Of theophylline's many activities, phos- phodiesterase inhibition may be the most important.Hypothetically, at least two therapeutically beneficial effects could result from inhibition of phosphodiesterase activity and the consequent rise in intracellular aden- osine 3',5'-monophosphate (cAMP) or guan- Cyclic AMP osine 3',5'-monophosphate (cGMP) concen- trations in key cells concerned in the pathophysiology of asthma (figure).Firstly, both cAMP and cGMP mediate airway smooth muscle relaxation,9 10 so a rise in either of these second messengers in airway smooth muscle should result in bronchodilatation.Secondly, the ability of PDE inhibitors to increase the cAMP content of inflammatory cells leads to an inhibition of cell activation.5 1112 In principle, then, PDE inhibitors should possess antiinflammatory activity.Although it is useful in the treatment of asthma, the value of theophylline is limited by a narrow therapeutic index and a wide range of gastrointestinal, central nervous system, and cardiovascular side effects.`4These sideeffects are generally ascribed to its lack of selectivity.Of particular importance in this respect is theophylline's ability to antagonise adenosine receptors and inhibit phosphodiesterase activity in inappropriate tissues (for example, gastrointestinal, central nervous sys- tem, cardiovascular).213 The development of drugs that couple the efficacy of theophylline CyclicGMP| Hormone Receptor
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bourne, H. R., Weinstein, Y., Melmon, K. L., Lichtenstein, L. M., Henney, C. S., & Shearer, G. M. (1974) · Science · doi:10.1126/science.184.4132.19 · Cited by 914
Beavo, J. A., & Reifsnyder, D. H. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90066-h · Cited by 849
Relationships between calcium and cyclic nucleotides in cell activation.
Rasmussen, H., & Goodman, D. B. (1977) · Physiological Reviews · doi:10.1152/physrev.1977.57.3.421 · Cited by 848
Zurier, R. B., Weissmann, G., Hoffstein, S. T., Kammerman, S., & Tai, H. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107550 · Cited by 588
Nicholson, C. D., Challiss, R. A. J., & Shahid, M. H. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90484-a · Cited by 457
IMMUNOLOGICAL RELEASE OF HISTAMINE AND SLOW REACTING SUBSTANCE OF ANAPHYLAXIS FROM HUMAN LUNG
Kaliner, M., Orange, R. P., & Austen, K. F. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.3.556 · Cited by 457
Are Methylxanthine Effects Due to Antagonism of Endogenous Adenosine?
Fredholm, B. B. (1979) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(79)90046-4 · Cited by 409
New Positive Inotropic Agents in the Treatment of Congestive Heart Failure
Colucci, W. S., Wright, R. F., & Braunwald, E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601303140506 · Cited by 397
Renz, H., Gong, J. H., Schmidt, A., Nain, M., & Gemsa, D. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.7.2388 · Cited by 394
New Positive Inotropic Agents in the Treatment of Congestive Heart Failure: (Second of Two Parts)
Colucci, W. S., Wright, R. F., & Braunwald, E. (1986) · New England Journal of Medicine · doi:10.1056/nejm198602063140605 · Cited by 341
Cited by
Lugnier, C. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.003 · Cited by 870
Phosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma Agents
TORPHY, T. J. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9708012 · Cited by 657
Self-citationCyclic nucleotide phosphodiesterases: Relating structure and function
Francis, S. H., Turko, I. V., & Corbin, J. D. (2000) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(00)65001-8 · Cited by 564
Boswell‐Smith, V., Spina, D., & Page, C. P. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706495 · Cited by 405
Therapeutic Potential of Boron-Containing Compounds
Baker, S. J., Ding, C. Z., Akama, T., Zhang, Y.-K., Hernandez, V., & Xia, Y. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.71 · Cited by 373
Houslay, M. D., Sullivan, M., & Bolger, G. B. (1998) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60128-3 · Cited by 290
Taming TNF: strategies to restrain this proinflammatory cytokine
Eigler, A., Sinha, B., Hartmann, G., & Endres, S. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)01118-3 · Cited by 284
Barnes, P. J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1524 · Cited by 280
Rabe, K. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01218.x · Cited by 273
Asthma: a follow up statement from an international paediatric asthma consensus group.
(1992) · Archives of Disease in Childhood · doi:10.1136/adc.67.2.240 · Cited by 262
Suttorp, N., Hippenstiel, S., Fuhrmann, M., Krull, M., & Podzuweit, T. (1996) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1996.270.3.c778 · Cited by 133
Metadata
- Authors
- Torphy, T. J., & Undem, B. J.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 1991-07-01
- Volume
- 46
- Issue
- 7
- Pages
- 512-523
- ISSN
- 0040-6376 (ISSN-L)
- OpenAlex
- W2164508592
- Cited by
- 380
- References
- 42
- FWCI
- 10.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.